Evaluation of Misoprostol Cytoprotection of the Bladder with Cyclophosphamide (Cytoxan) Therapy

Foad, 1976, Urinary bladder complications with CY therapy, Arch. Intern. Med., 136, 616, 10.1001/archinte.1976.03630050090015

Klein, 1983, Urinary complications of cyclophosphamide therapy: etiology, prevention, and management, South. Med. J., 76, 1413, 10.1097/00007611-198311000-00022

Brock, 1981, Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention, Eur. J. Cancer Clin. Oncol., 17, 1155, 10.1016/S0277-5379(81)80019-3

Cox, 1979, Cyclophosphamide cystitis—identification of acrolein as the causative agent, Biochemical Pharmacol., 28, 2045, 10.1016/0006-2952(79)90222-3

Droller, 1982, Prevention of cyclophos phamide—induced hemorrhagic cystitis, Urology, 20, 256, 10.1016/0090-4295(82)90633-1

Sladek, 1982, Influence of diuretics on urinary general base catalytic activity and cyclophosphamide—induced bladder toxicity, Cancer Treat. Rep., 66, 1889

Tolley, 1977, The effect of N-acetyl cysteine on cyclophosphamide cystitis, Br. J. Urol., 49, 659, 10.1111/j.1464-410X.1977.tb04548.x

Hacker, 1982, The prevention of cyclophosphamide—induced cystitis in mice by disulfiram, Res. Comm. Chem. Path. Pharm., 35, 145

Brock, 1983, The development of mesna for regional detoxification, Cancer Treat. Rev., 10, 33, 10.1016/S0305-7372(83)80005-X

Brock, 1981, Studies on the urotoxicity of oxazaphorphorine cytostatics and its prevention, Eur. J. Cancer Clin. Oncol., 17, 1155, 10.1016/S0277-5379(81)80019-3

Hows, 1983, Mesna versus forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplant patients, Cancer Treat. Rev., 10, 53, 10.1016/S0305-7372(83)80007-3

Blacklock, 1983, Experience with mesna in patients receiving allogeneic bone marrow transplants for poor prognostic leukemia, Cancer Treat. Rev., 10, 45, 10.1016/S0305-7372(83)80006-1

Schmahl, 1983, Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna, Cancer Treat. Rev., 10, 57, 10.1016/S0305-7372(83)80008-5

Habs, 1983, Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2.2′-dithiobisethane sulfonate (dimesna), Cancer, 51, 606, 10.1002/1097-0142(19830215)51:4<606::AID-CNCR2820510409>3.0.CO;2-S

Millar, 1983, Studies on the toxicity of cyclophosphamide in combination with mesna in vitro and in vivo, Cancer Treat. Rev., 10, 63, 10.1016/S0305-7372(83)80009-7

Botta, 1973, Acetylcysteine in the prevention of cyclophosphamide-induced cystitis in rats, J. Natl. Cancer Inst., 51, 1051, 10.1093/jnci/51.3.1051

Raskin, D. J. and Gray, K. J.: Cytoprotection of the urinary bladder with 16,16 dimethyl prostaglandin E2 during cyclophosphamide therapy. Presented at Canadian Urological Association, Toronto, Ontario, 39th Annual Meeting, June 10–14, 1984.

Guth, 1983, Prostaglandin cytoprotection: prostaglandin does not protect against aspirin or alcohol-induced red blood cell hemolysis, Dig. Dis. and Sci., vol. 28, 10.1007/BF01317041

Personal communication with Ray Bauer, Ph.D., Searle Research & Development, Division of G. D. Searle & Co., 4901 Searle Parkway, Skokie, Illinois, 60077.

Bonta, 1978, Prostaglandins and chronic inflammation, Biochem. Pharmacol., 27, 1611, 10.1016/0006-2952(78)90169-7

Kaye, 1980, Water diuresis is a major regulator of prostaglandin E excretion in man, Advances in Prostaglandin and Thromboxane Research, 7, 1017

Mohuiddon, 1984, Treatment of cyclophosphamide-induced cystitis with prostaglandin E2, Ann. Intern. Med., 101, 142, 10.7326/0003-4819-101-1-142_1